Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma Meeting Abstract
| Authors: | Janjigian, Y. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J. P.; Yanez Weber, P. E.; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; Bilici, M.; Chung, H. C.; Shitara, K.; Mahave, M.; Van Cutsem, E.; Tabernero, J.; Xu, L.; Sharan, K.; Bhagia, P.; Rha, S. Y. |
| Abstract Title: | Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S877 |
| End Page: | S878 |
| Language: | English |
| ACCESSION: | WOS:001326612902022 |
| DOI: | 10.1016/j.annonc.2024.08.1466 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1400O -- Source: Wos |
